WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.227.251.94'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

Champignon Brands Inc. – Shroom Investor 🍄

Champignon Brands Inc.

Champignon Brands Inc.

Review of Bipolar Disorders Confirms Early Diagnosis and Treatment Can Improve Patient Quality of Life

VANCOUVER, BC, Jan. 8, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announces the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article – Bipolar Disorders – is published in one of the world's best-known and most reputable scientific journals in medicine - T... Read More...

Champignon Provides Update on Disclosure Review

VANCOUVER, British Columbia, Sept. 15, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review. Since the review was commenced, the Company has arranged for:Filing of business acquisition reports (coll... Read More...

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence

VANCOUVER, British Columbia, Aug. 27, 2020 -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September 2020. Ketamine was declare... Read More...

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

VANCOUVER, British Columbia, July 24, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of t... Read More...

Champignon Announces Regulatory Review

VANCOUVER, British Columbia, June 22, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became ... Read More...

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals

VANCOUVER, British Columbia, June 19, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (MDD) ... Read More...

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

VANCOUVER, British Columbia, June 12, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiat... Read More...

Champignon Announces Closing of $15 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, June 11, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is please... Read More...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

VANCOUVER, British Columbia, June 08, 2020 -- Champignon Brands Inc. (“Champignon” or the “Company”) (SHRM.CN) (496.F) (SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemi... Read More...